As of 2025-07-10, the Relative Valuation of Inozyme Pharma Inc (INZY) is (22.15) USD. This relative valuation is based on P/E multiples. With the latest stock price at 4.00 USD, the upside of Inozyme Pharma Inc based on Relative Valuation is -653.7%.
The range of the Relative Valuation is (16.96) - (30.78) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 8.7x - 18.6x | 13.1x |
| Forward P/E multiples | 10.3x - 21.3x | 13.7x |
| Fair Price | (16.96) - (30.78) | (22.15) |
| Upside | -524.0% - -869.5% | -653.7% |
| Date | P/E |
| 2025-06-30 | -2.42 |
| 2025-06-27 | -2.41 |
| 2025-06-26 | -2.42 |
| 2025-06-25 | -2.41 |
| 2025-06-24 | -2.41 |
| 2025-06-23 | -2.41 |
| 2025-06-20 | -2.41 |
| 2025-06-18 | -2.41 |
| 2025-06-17 | -2.41 |
| 2025-06-16 | -2.40 |
| 2025-06-13 | -2.41 |
| 2025-06-12 | -2.41 |
| 2025-06-11 | -2.40 |
| 2025-06-10 | -2.41 |
| 2025-06-09 | -2.41 |
| 2025-06-06 | -2.41 |
| 2025-06-05 | -2.41 |
| 2025-06-04 | -2.41 |
| 2025-06-03 | -2.41 |
| 2025-06-02 | -2.40 |
| 2025-05-30 | -2.40 |
| 2025-05-29 | -2.39 |
| 2025-05-28 | -2.39 |
| 2025-05-27 | -2.39 |
| 2025-05-23 | -2.40 |
| 2025-05-22 | -2.40 |
| 2025-05-21 | -2.39 |
| 2025-05-20 | -2.39 |
| 2025-05-19 | -2.41 |
| 2025-05-16 | -2.39 |
| 2025-05-15 | -0.86 |
| 2025-05-14 | -0.82 |
| 2025-05-13 | -0.66 |
| 2025-05-12 | -0.71 |
| 2025-05-09 | -0.70 |
| 2025-05-08 | -0.75 |
| 2025-05-07 | -0.80 |
| 2025-05-06 | -0.76 |
| 2025-05-05 | -0.90 |
| 2025-05-02 | -0.98 |
| 2025-05-01 | -0.73 |
| 2025-04-30 | -0.70 |
| 2025-04-29 | -0.64 |
| 2025-04-28 | -0.58 |
| 2025-04-25 | -0.60 |
| 2025-04-24 | -0.58 |
| 2025-04-23 | -0.59 |
| 2025-04-22 | -0.62 |
| 2025-04-21 | -0.59 |
| 2025-04-17 | -0.56 |